NO981008L - Farmas÷ytisk formulering - Google Patents

Farmas÷ytisk formulering

Info

Publication number
NO981008L
NO981008L NO981008A NO981008A NO981008L NO 981008 L NO981008 L NO 981008L NO 981008 A NO981008 A NO 981008A NO 981008 A NO981008 A NO 981008A NO 981008 L NO981008 L NO 981008L
Authority
NO
Norway
Prior art keywords
isk
pharmaceutical
surface formulation
formulation
pharmaceutical isk
Prior art date
Application number
NO981008A
Other languages
English (en)
Other versions
NO981008D0 (no
NO314831B1 (no
Inventor
Daniel Joseph Burch
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21705455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO981008(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO981008D0 publication Critical patent/NO981008D0/no
Publication of NO981008L publication Critical patent/NO981008L/no
Publication of NO314831B1 publication Critical patent/NO314831B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO19981008A 1995-09-07 1998-03-06 Farmasöytisk formulering, samt fremgangsmåte for fremstilling og anvendelsederav NO314831B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US335395P 1995-09-07 1995-09-07
PCT/US1996/014554 WO1997009042A1 (en) 1995-09-07 1996-09-05 Pharmaceutical formulation

Publications (3)

Publication Number Publication Date
NO981008D0 NO981008D0 (no) 1998-03-06
NO981008L true NO981008L (no) 1998-05-06
NO314831B1 NO314831B1 (no) 2003-06-02

Family

ID=21705455

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981008A NO314831B1 (no) 1995-09-07 1998-03-06 Farmasöytisk formulering, samt fremgangsmåte for fremstilling og anvendelsederav

Country Status (28)

Country Link
US (3) US6726908B2 (no)
EP (3) EP1093812A3 (no)
JP (1) JP3501289B2 (no)
KR (1) KR100495585B1 (no)
CN (1) CN1289084C (no)
AR (1) AR004510A1 (no)
AT (1) ATE208618T1 (no)
AU (1) AU711441B2 (no)
BR (1) BR9610396A (no)
CA (1) CA2231194C (no)
CO (1) CO4750658A1 (no)
CY (1) CY2359B1 (no)
CZ (1) CZ299595B6 (no)
DE (1) DE69617036T2 (no)
DK (1) DK0862431T3 (no)
ES (1) ES2165997T3 (no)
HK (2) HK1015701A1 (no)
HU (1) HUP9901437A3 (no)
IL (1) IL123563A (no)
NO (1) NO314831B1 (no)
NZ (3) NZ318282A (no)
PL (1) PL325411A1 (no)
PT (1) PT862431E (no)
SI (1) SI0862431T1 (no)
TR (1) TR199800415T1 (no)
TW (1) TW501926B (no)
WO (1) WO1997009042A1 (no)
ZA (1) ZA967546B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
EP1093812A3 (en) * 1995-09-07 2001-06-06 SmithKline Beecham Corporation Amoxycillin and clavulanate containing pharmaceutical formulation
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
GB2365337A (en) * 1999-04-13 2002-02-20 Beecham Pharma Amoxycillin and potassium clavulanate high dosage regimen
BE1013309A5 (fr) * 1999-04-13 2001-11-06 Beecham Pharm Pte Ltd Formulations pharmaceutiques nouvelles comprenant l'amoxycilline et du clavulanate de potassium.
WO2001000177A1 (en) * 1999-06-29 2001-01-04 Micio Pharma Chemical Aktiengesellschaft Retard formulation of amoxicillin for oral administration
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
WO2013057569A2 (en) 2011-10-19 2013-04-25 Micro Labs Limited Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
KR20140117523A (ko) * 2012-01-10 2014-10-07 마이클 스펙터 아목시실린 및 클라불란산 칼륨의 소아용 경구 현탁 제형 및 이를 사용하기 위한 방법
WO2013173803A2 (en) * 2012-05-17 2013-11-21 Michael Spector Formulations of amoxicillin and clavulanate potassium and methods for using same
WO2013173808A2 (en) * 2012-05-17 2013-11-21 Michael Spector Methods for use of lower dose compositions of amoxicillin and clavulanate potassium and devices for use
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) * 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
JO984B1 (en) 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
IL58461A0 (en) 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3266580D1 (en) * 1981-12-02 1985-10-31 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
US4673637A (en) 1984-04-23 1987-06-16 Hyman Edward S Method for detecting bacteria in urine and for treating rheumatoid arthritis, essential hypertension and other diseases associated with bacteriuria
DE3887179T2 (de) 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US5114929A (en) 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
KR910009271B1 (ko) 1989-06-20 1991-11-08 김영설 1,1-디옥소페닐실라노일 옥시메틸 D-6-[α-(메틸렌아미노)페닐-아세트아미도]-페니실라네이트와 그의 파라-톨루엔술폰산염
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
US5814337A (en) * 1992-10-07 1998-09-29 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9114950D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Pharmaceutical formulation
WO1994016696A1 (en) * 1993-01-22 1994-08-04 Smithkline Beecham Plc Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
GB9311030D0 (en) 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9405856D0 (en) 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
DZ1926A1 (fr) 1994-09-03 2002-02-17 Smithkline Beckman P L C Formulations pharmaceutiques.
DZ2028A1 (fr) 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US5830073A (en) 1995-07-28 1998-11-03 Voss; Brian C. Bowling lane surfaces
EP1093812A3 (en) * 1995-09-07 2001-06-06 SmithKline Beecham Corporation Amoxycillin and clavulanate containing pharmaceutical formulation
IL131201A (en) 1997-02-14 2005-06-19 Smithkline Beecham Lab Pharmaceutical formulations comprising amoxycillin and clavulanate
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
ID22340A (id) 1997-03-25 1999-09-30 Takeda Chemical Industries Ltd Komposisi farmasi lekat-mukosa saluran pencernaan
GB9815532D0 (en) 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
BE1013309A5 (fr) * 1999-04-13 2001-11-06 Beecham Pharm Pte Ltd Formulations pharmaceutiques nouvelles comprenant l'amoxycilline et du clavulanate de potassium.

Also Published As

Publication number Publication date
EP1093812A2 (en) 2001-04-25
DE69617036D1 (de) 2001-12-20
DE69617036T2 (de) 2002-07-11
AR004510A1 (es) 1998-12-16
NZ337246A (en) 2000-07-28
HUP9901437A2 (hu) 1999-09-28
KR100495585B1 (ko) 2005-09-09
EP1093812A3 (en) 2001-06-06
PL325411A1 (en) 1998-07-20
WO1997009042A1 (en) 1997-03-13
AU6973396A (en) 1997-03-27
NZ318282A (en) 2000-01-28
JP3501289B2 (ja) 2004-03-02
EP0862431A4 (en) 1999-07-07
KR19990044495A (ko) 1999-06-25
IL123563A (en) 2002-02-10
US20010043926A1 (en) 2001-11-22
CN1289084C (zh) 2006-12-13
ZA967546B (en) 1998-03-06
CA2231194A1 (en) 1997-03-13
US6726908B2 (en) 2004-04-27
EP1147771A1 (en) 2001-10-24
US20050261267A1 (en) 2005-11-24
TW501926B (en) 2002-09-11
AU711441B2 (en) 1999-10-14
HK1015701A1 (en) 1999-10-22
TR199800415T1 (en) 1998-05-21
CO4750658A1 (es) 1999-03-31
CN1200672A (zh) 1998-12-02
PT862431E (pt) 2002-04-29
SI0862431T1 (en) 2002-06-30
CA2231194C (en) 2004-07-20
CZ68398A3 (cs) 1998-07-15
HK1043042A1 (zh) 2002-09-06
DK0862431T3 (da) 2002-03-11
US20010038838A1 (en) 2001-11-08
ATE208618T1 (de) 2001-11-15
NO981008D0 (no) 1998-03-06
NZ337247A (en) 2001-05-25
CZ299595B6 (cs) 2008-09-17
HUP9901437A3 (en) 2000-03-28
BR9610396A (pt) 1999-07-06
NO314831B1 (no) 2003-06-02
EP0862431B1 (en) 2001-11-14
MX9801903A (es) 1998-05-31
ES2165997T3 (es) 2002-04-01
CY2359B1 (en) 2004-06-04
JPH11512398A (ja) 1999-10-26
EP0862431A1 (en) 1998-09-09

Similar Documents

Publication Publication Date Title
NO981008L (no) Farmas÷ytisk formulering
NO982302D0 (no) Farmas÷ytisk sammensetning
BR9611367A (pt) Formulação farmacêutic liofilizada estável
DE69525148D1 (de) Pharmazeutische formulierung
BR9610153A (pt) Formulações farmacêuticas
DE69607031D1 (de) Reiniger
ID24654A (id) Formulasi farmasi omeprazola
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
PT978276E (pt) Comprimidos com revestimento de polimero que compreendem amoxicilina e clavulanato
NO20021172D0 (no) Farmasöytisk sammensetning
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
NO985539L (no) Farmas÷ytiske blandinger
ATA181095A (de) Probiotisch wirksame formulierung
NO973471D0 (no) Transdermal formulering
FI973362A (fi) Transdermaalinen formula
BR9600809A (pt) Medicamento
DE69614407D1 (de) Pharmazeutische zusammensetzungen
LV11727A (lv) Farmaceitiska kompozicija
ATE258010T1 (de) Pestizide formulierung
DE69430362D1 (de) Ektoparasitizide formulierung
DK0772988T3 (da) Stol
FI973280A (fi) Farmaseuttinen koostumus
FI973230A (fi) Uusi farmaseuttinen formulaatio
BR9606066A (pt) Composto e formulação farmacêutica
BR9605777A (pt) Composição farmacêutica

Legal Events

Date Code Title Description
MK1K Patent expired